Boston Scientific Launches Victory Guidewire For Crossing Resistant Lesions In Peripheral Arteries Victory™ guidewires are designed to facilitate crossing of resistant lesions
NATICK, Mass., Oct. 9, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing of resistant lesions and the placement and exchange of balloon catheters or other interventional devices within the peripheral vasculature. The company expects to launch the product in other international markets later this year and in 2013, subject to regulatory approvals.
An estimated 17.6 million Americans suffer from peripheral artery disease, which is characterized by blockage or narrowing in vessels of the peripheral vasculature, frequently associated with high rates of morbidity and mortality. Critical limb ischemia (CLI) is a serious condition affecting an increasing number of patients worldwide. CLI patients have multi-vessel disease and challenging lesions, which, if left untreated, can lead to limb loss. In the United States, an estimated 25 percent of patients with peripheral artery disease will require amputation within one year of onset of CLI. Saving limbs through surgery or endovascular techniques improves the quality of life for patients.
"Resistant lesions can be a challenge and I often need various tools to access, cross and treat these types of lesions," said Derek Mittleider, M.D., Interventional Radiologist, Director, Vascular and Interventional Radiology, Spectrum Medical Group. "The Victory wire's high gram-load options and excellent torque-ability give me the extra push and steer-ability I need to get through these resistant lesions more easily, making these cases less challenging."
The Victory guidewires feature a broad matrix of high gram-load tip options ranging from 12g to 30g, designed to cross resistant lesions. A unique stainless steel core technology enables this wire to have superior torque for optimal steering and control. Hydrophilic coating provides enhanced lubricity to facilitate crossing resistant lesions. The Victory guidewires come in both 0.014" and 0.018" diameters with four different gram-load options offering clinical versatility and a range of pushability.
"Physicians treating CLI patients typically require a variety of treatment options. Boston Scientific is committed to offering a wide variety of crossing solutions," said Jeff Mirviss, president of the Boston Scientific Peripheral Interventions Division. "Victory guidewires complement our already broad portfolio of crossing solutions, inclusive of our market-leading angioplasty balloons, Rubicon™ Support Catheter and the TruePath™ CTO device. The Victory guidewires offer another option to cross these highly resistant lesions and potentially avoid the need for amputation."
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, markets for our products, new product launches and launch cadence, regulatory approvals, product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Boston Scientific Corporation